On February 5th, project partners from LWNVIVAT gathered at Palau Macaya for the General Assembly Meeting. The event focused on discussing advancements in developing recombinant vaccines and therapeutic antibodies to combat West Nile virus (WNV) infection.

Discussions covered key topics such as the design of novel structured immunogens targeting WNV, the production and purification of recombinant envelope immunogens, and the development of virus-like particles (VLPs) containing selected immunogens. Researchers also presented findings on the in vitro immunogenicity of WNV protein candidates and explored strategies to enhance communication and dissemination, ensuring that scientific advancements reach a wider audience.

Institutions involved in the project, including Braunschweig University, Barcelona Supercomputing Centre, Hipra, INSERM, IrsiCaixa, the University of Montpellier, and the University of Copenhagen, shared their latest findings, emphasizing the importance of continued collaboration in the fight against emerging viral threats.

As vector-borne diseases remain a global health concern, projects like LWNVIVAT play a crucial role in developing effective solutions. The progress shared at this meeting highlights the dedication of researchers in combating WNV and other emerging pathogens.